NASDAQ:RPTX Repare Therapeutics (RPTX) Stock Price, News & Analysis $1.61 +0.03 (+1.90%) Closing price 04:00 PM EasternExtended Trading$1.62 +0.00 (+0.31%) As of 05:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Repare Therapeutics Stock (NASDAQ:RPTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Repare Therapeutics alerts:Sign Up Key Stats Today's Range$1.56▼$1.6350-Day Range$1.37▼$1.5952-Week Range$0.89▼$4.07Volume178,564 shsAverage Volume303,598 shsMarket Capitalization$69.16 millionP/E RatioN/ADividend YieldN/APrice Target$4.50Consensus RatingModerate Buy Company Overview Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada. Read More Repare Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreRPTX MarketRank™: Repare Therapeutics scored higher than 41% of companies evaluated by MarketBeat, and ranked 671st out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingRepare Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageRepare Therapeutics has received no research coverage in the past 90 days.Read more about Repare Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Repare Therapeutics are expected to decrease in the coming year, from ($2.04) to ($2.96) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Repare Therapeutics is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Repare Therapeutics is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRepare Therapeutics has a P/B Ratio of 0.45. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Repare Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.23% of the float of Repare Therapeutics has been sold short.Short Interest Ratio / Days to CoverRepare Therapeutics has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Repare Therapeutics has recently increased by 22.11%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRepare Therapeutics does not currently pay a dividend.Dividend GrowthRepare Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.23% of the float of Repare Therapeutics has been sold short.Short Interest Ratio / Days to CoverRepare Therapeutics has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Repare Therapeutics has recently increased by 22.11%, indicating that investor sentiment is decreasing significantly. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Repare Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for RPTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Repare Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders11.50% of the stock of Repare Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions85.09% of the stock of Repare Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Repare Therapeutics' insider trading history. Receive RPTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Repare Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RPTX Stock News HeadlinesRepare Therapeutics Announces Licensing Deal and Strategic UpdatesAugust 12, 2025 | theglobeandmail.comRepare (RPTX) Q2 Loss Narrows 52%August 8, 2025 | fool.comA Major Economic Change Is Happening NowLouis Navellier is one of Wall Street’s most respected money managers — overseeing more than $7 billion and earning a reputation for fact-based analysis, not sensationalism. That’s why his latest economic warning is turning so many heads. In his new report, Louis reveals how recent policies are accelerating a massive economic shift. While headlines point to strong numbers, everyday Americans feel the squeeze as prices climb and industries are reshaped. According to Louis, this transformation could determine who falls behind — and who builds lasting wealth.August 26 at 2:00 AM | InvestorPlace (Ad)Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial ResultsAugust 8, 2025 | financialpost.comFRepare Therapeutics Jumps 15% After $10M Licensing Deal With DebiopharmJuly 18, 2025 | uk.finance.yahoo.comRepare Therapeutics Inc. (RPTX) - Yahoo FinanceJuly 17, 2025 | finance.yahoo.comRepare Therapeutics Jumps After Hours On $267M Global Licensing Deal With Debiopharm; Retail Traders Rush InJuly 16, 2025 | msn.comRepare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for LunresertibJuly 15, 2025 | financialpost.comFSee More Headlines RPTX Stock Analysis - Frequently Asked Questions How have RPTX shares performed this year? Repare Therapeutics' stock was trading at $1.31 at the start of the year. Since then, RPTX shares have increased by 22.9% and is now trading at $1.61. How were Repare Therapeutics' earnings last quarter? Repare Therapeutics Inc. (NASDAQ:RPTX) issued its quarterly earnings data on Friday, August, 8th. The company reported ($0.39) earnings per share for the quarter, beating analysts' consensus estimates of ($0.56) by $0.17. The business had revenue of $0.25 million for the quarter, compared to analysts' expectations of $2.50 million. When did Repare Therapeutics IPO? Repare Therapeutics (RPTX) raised $126 million in an initial public offering (IPO) on Friday, June 19th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Goldman Sachs, Cowen and Piper Sandler served as the underwriters for the IPO. Who are Repare Therapeutics' major shareholders? Top institutional investors of Repare Therapeutics include Redmile Group LLC (3.69%), Rangeley Capital LLC (0.83%), Militia Capital Partners LP (0.28%) and XTX Topco Ltd (0.10%). Insiders that own company stock include Bvf Partners L P/Il, Lloyd Mitchell Segal, Michael Zinda and Steve Forte. View institutional ownership trends. How do I buy shares of Repare Therapeutics? Shares of RPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Repare Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Repare Therapeutics investors own include Waste Connections (WCN), American Water Works (AWK), AU Optronics (AUOTY), The RMR Group (RMR), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH) and Humana (HUM). Company Calendar Last Earnings8/08/2025Today8/26/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RPTX CIK1808158 Webwww.reparerx.com Phone857-412-7018FaxN/AEmployees180Year Founded2016Price Target and Rating Average Price Target for Repare Therapeutics$4.50 High Price Target$5.00 Low Price Target$4.00 Potential Upside/Downside+179.5%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($2.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$84.69 million Net MarginsN/A Pretax Margin-43,504.40% Return on Equity-78.25% Return on Assets-66.85% Debt Debt-to-Equity RatioN/A Current Ratio6.30 Quick Ratio6.30 Sales & Book Value Annual Sales$250 thousand Price / Sales276.66 Cash FlowN/A Price / Cash FlowN/A Book Value$3.56 per share Price / Book0.45Miscellaneous Outstanding Shares42,959,000Free Float38,019,000Market Cap$69.16 million OptionableOptionable Beta0.93 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:RPTX) was last updated on 8/26/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBREAKING: Meta, Apple and NASA rush to invest in new "E.I." techBig Tech and even NASA are racing to back a breakthrough known as “E.I. Tech,” set to launch September 1st. Ex...Behind the Markets | SponsoredTrump’s national nightmare is hereWhile the headlines focus on global conflicts, there’s a very different crisis brewing at home. Washington has...Porter & Company | SponsoredIt’s game over for Central BanksCentral banks are losing control. Inflation isn’t fixed, debt is exploding, and stocks have never looked more ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repare Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Repare Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.